Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2003-12-10
2010-10-12
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S200000, C552S576000
Reexamination Certificate
active
07812009
ABSTRACT:
A pharmaceutical composition for intramammary administration to a nonhuman mammal comprising an antibacterial agent and prednisolone, wherein the composition comprises at least 20 mg of prednisolone, and its use for the treatment of clinical mastitis.
REFERENCES:
patent: 4112073 (1978-09-01), Ono
patent: 1 585 497 (2008-03-01), None
Lohuis, J.A.C.M. et al: “Effect of Steroidal Anti-Inflammatory Drugs onEscherichia coli. . . ” J. of Dairy Science, (Jan. 1989) Amer. Dairy Science Assoc. V72, N1, p. 241-249.
Farnsworth, R.J. et al: “The Effect of Penicillin, Dihydrostreptomycin and Prednisolone Treatment . . . ” Canadian J. of Comparative Medicine-Revue, (Jul. 1975) V39, N3 p. 340-348.
Faull, W.B. et al: “Treatment of clinical mastitis: Two intramammary formulations compared” Veterinary Record, British Veterinary Assoc.(Feb. 8, 1975) V96, N6 p. 127-129.
Hornish, R.E. et al: Cephalosporins in Veterinary Medicine-Ceftiofur Use in Food . . . (Jul. 2002) Current Topics in Medicinal Chemistry, Bentham Sci. Pub. V2, N7,p. 717-731, NL.
Breitschwerdt et al., Prednisolone at Anti-Inflammatory or Immunosuppressive Dosages in Conjunction with Doxycycline Does Not Potentiate the Severity ofRickettsia rickettsiiinfections in Dogs, Antimicrobial Agents and Chemotherapy, Jan. 1997, pp. 141-147, vol. 41, No. 1.
Geleta et al., Excretion of [3H]prednisolone in clinically normal and experimentally infected bovine udders, Am. J. Vet. Res., Aug. 1984, vol. 45, No. 8.
Orden et al., In Vitro Activities of Cephalosporins and Quinolones againstEscherichia coliStrains Isolated from Diarrheic Dairy Calves, Antimicrobial Agents and Chemotherapy, Mar. 1999, pp. 510-513, vol. 43, No. 3.
Shpigel et al., Efficacy of Cefquinome for Treatment of Cows with Mastitis Experimentally Induced UsingEscherichia coli, J. Dairy Sci., pp. 318-325, vol. 80.
Matsuda et al., Abstract, Combination Chemotherapy for Klebsiella Mastitis, Journal of Veterinary Medicine, Japan, 1995, pp. 985-988, vol. 48, No. 12.
Summary of Product Characteristics of Product CEPHAGUARD LC, marketing authorization of 2001.
Report on prednisolone issued by the Committee for veterinary medicinal products, EMEA/MRL/629/99-FINAL, published in Jul. 1999.
Notice of Opposition in French and Notice of Opposition in English for European patent No. 1 585 497 B1.
Opposition response dated Jul. 30, 2009.
Cox Peter Gerardus Franciscus
Hensen Selma Marianne
Lohuis Joseph Antonius Clemens Maria
Gryte David M.
Intervet International B.V.
Jean-Louis Samira
Padmanabhan Sreeni
Turner Allen C.
LandOfFree
Mastitis treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mastitis treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mastitis treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4191257